Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

By S. Verstappen, J. Jacobs, M. Veen, A. Heurkens, Y. Schenk, E. Borg, A. Blaauw, J. Bijlsma. Annals of the Rheumatic Diseases, 2007

623 citations recorded by the source corpus.

Citations in the corpus

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, neutral): “(13) Tapering of synthetic DMARDs—This statement follows the preceding one, suggesting that tapering synthetic DMARD treatment in cases of longstanding remission could be considered after GCs and biological agents have been discontinued.”
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, neutral): “and later by showing that tight control using composite measures of disease activity and appropriate switching of drug treatment are highly efficacious approaches.”
Treating rheumatoid arthritis to target: recommendations of an international task force (2010, neutral): “28 29 However, the Expert Committee felt that, while being an important step and a major alternative goal, reaching LDA could only pertain to patients with long-standing RA whose disease may have become refractory to therapeutic intervention.”